Nephrologist and Scientist with great interest in immune cell mediated kidney diseases. Proud Mum of two Kids. @kathrin_eller@mastodon.world
Joined January 2017
- Tweets873
- Following394
- Followers652
- Likes1.7K
Kathrin Eller retweeted
The Avacopan Fraud Story from my Update in Nephrology 2026: What's New in NephronTown
youtu.be/cf1uenkWpYU?si=65Bp…
Kathrin Eller retweeted
We are looking for a highly motivated postdoctoral researcher to join our team at the Medical University of Vienna.
The translational project will investigate how metabolic programs regulate granuloma formation and disease progression in sarcoidosis.
🤖 Made with AI
Kathrin Eller retweeted
Read this! It is very interesting and very inclusive!
The “Knowledge Exchange” is a great opportunity for experts <56 in one field to visit another institution, see how a specific area of nephrology is approached, and establish meaningful professional networks.
📢 The call for ERA fellowships is now open!
ERA offers exiting opportunities:
🔬Long-term research fellowships (up to 40 years of age)
📊 ERA Registry fellowship (up to 50 years of age)
📚 Knowledge Exchange Programme (up to 55 years of age)
🚨 Applications are open only to ERA active Full members
Apply by March 20, 2026 👉 bit.ly/41lRD6v
Kathrin Eller retweeted
Imlifidase add-on to SoC does not improve kidney function compared to SoC alone in pts with rapid progressive anti-GBM disease says a press release of Hansa Biopharma. hansabiopharma.com/media/pre…
Kathrin Eller retweeted
In Podocytopathies, histology labels lesions—etiology dictates therapy. Time for an etiology-based classification. Our new review just out in Nat Rev Dis Primers:
nature.com/articles/s41572-0…
#Nephrology #PrecisionMedicine #KidneyDisease
Kathrin Eller retweeted
🚨 Just out from our lab in @CircAHA! 🚨 We know APOL1 risk variants (RVs) cause FSGS. But what about Hypertension-Attributed Kidney Disease (H-CKD)? 🤔 H-CKD is distinct: slowly progressing, low albuminuria, and massive vascular damage. Is it just secondary to kidney injury? Or is it a primary vascular defect? We found the answer.🧵👇ahajournals.org/eprint/TNWJK…
Kathrin Eller retweeted
Summary: Our lab resolves the dichotomy of APOL1 nephropathy: 1️⃣ Podocyte Expression ➡️ FSGS (High Proteinuria). 2️⃣ Endothelial Expression ➡️ Primary Hypertension & H-CKD (Low Proteinuria).
We identified the STING-Endothelin axis as the specific driver of the vascular phenotype, opening new doors for targeted treatment. 🚀
Kathrin Eller retweeted
This is impressive CV risk reduction with Tirzepatide vs Semaglutide
The fact that we have these incretin therapies available is a game changer. Now we just have to make them accessible and cheaper #GLP1RA #weightloss #CVRisk #CVPrev #cardiotwitter
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial ow.ly/5bL850XiWTZ
@ehjopen @SaDeRosa78 @ProfMagnusBack @SABOURETcardio #EHJOpen
Kathrin Eller retweeted
Results from the evoke trials with oral semaglutide #Alzheimersdisease are imminent. The real world data continues to arrive for GLP-1 medicines and #T2D cardiab.biomedcentral.com/ar…
Kathrin Eller retweeted
Is a 43 % Risk Reduction of serious CVE with 1.6 g of EPA and 0.8 g of DHA a major breakthrough in cardiorenal medicine or potentially rather a fishy finding?
Here comes PESCES
nejm.org/doi/full/10.1056/NE…
Kathrin Eller retweeted
That's so sad. I'm sure so many more people would've come.
I let this here for the contrast #kideywk
xitter.cf/ERAkidney/status/19309…
🎉Late Breaking Clinical Trials II at #ERA25 is officially at capacity with over 3,000 delegates👏
💥This milestone proves one thing: nephrology is going beyond boundaries and beyond expectations.
To everyone in the room: you’re part of history.
To everyone online: stay tuned — the breakthroughs are just beginning.
#BeyondNephrology
Kathrin Eller retweeted
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial"
Read more: kidney.pub/JASN0924
Kathrin Eller retweeted
Rituximab for Relapsing Nephrotic Syndrome in AdultsA Randomized Clinical Trial jamanetwork.com/journals/jam…
Kathrin Eller retweeted
Simultaneous publication in JAMA!
jamanetwork.com/journals/jam…
Kathrin Eller retweeted
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… @NEJM @ASNKidney #kidneyweek25
Kathrin Eller retweeted
New episode of Channel Your Enthusiasm, part 2 of 3 on metabolic acidosis. Episode with chapters, chapter art, and fully it is referenced (as usual)
rosebook.club/episodes/2025/…
Take a look at our most recent work providing insights why patients with West african ancestry are more likely to develop aggressive glomerulonephritis. Thanks to all co-authors!!!
In #ASNJASN: Erythroid ACKR1 Deficiency Aggravates Immune-Mediated Kidney Disease. Read more about how selective erythroid ACKR1 deficiency exacerbated disease activity in experimental glomerulonephritis via changes of the myeloid lineage: kidney.pub/JASN0878 #BasicResearch
Kathrin Eller retweeted
The Austrian Society of Nephrology (ÖGN) just published their Guidelines for CKD🎉
shorturl.at/hGtLt
@MarcusSaemann @m_windp @e_zitt @EllerKathrin @AntMarlies @RainerOberbauer @Christo46109236 @SabineSchmaldi1 @YNAnephro – at Austria
